Two-Drug combo aims to stall rare gut tumors

NCT ID NCT00113360

Completed Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests whether combining two drugs—RAD001 (everolimus) and octreotide depot—can slow tumor growth in people with advanced low-grade neuroendocrine cancer (carcinoid or islet cell tumors) that has spread or cannot be removed surgically. Participants take RAD001 daily by mouth and receive octreotide injections every 28 days. The study measures how long the cancer stays under control and monitors safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Everolimus (RAD001) plus octreotide depot
What this could lead to: If it works, this combination could offer a new way to slow tumor growth and extend time without progression for people with advanced neuroendocrine cancer.
What could go wrong: This is a Phase 2 trial, so the combination may not prove effective or safe enough for broader use. Side effects from the drugs are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoid tumor neuroendocrine carcinoma pancreatic endocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISLET CELL CARCINOMA NEUROENDOCRINE; CARCINOMA

Contacts and locations

Show contact details

Locations

UT MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.